荷兰淋巴浆细胞淋巴瘤/华氏巨球蛋白血症1989-2018年一线治疗与相对生存的人群研究
该研究基于荷兰全国癌症登记数据,分析了1989-2018年诊断为淋巴浆细胞淋巴瘤/华氏巨球蛋白血症的6232例患者的一线治疗趋势和相对生存。结果显示,随着利妥昔单抗的引入和化疗免疫治疗的增加,5年相对生存显著改善,但2011年后改善幅度减弱。
要点
- 初始观察等待策略的应用逐渐增加,2011-2018年仅约40%患者接受抗肿瘤治疗。
- 地塞米松-利妥昔单抗-环磷酰胺是最常用方案,2014-2018年使用率从14%升至39%。
- 5年相对生存随年龄组改善,2011-2018年<65、66-75和>75岁分别为93%、85%和79%。
核心结论
- 生存改善可能归因于含利妥昔单抗治疗的广泛应用。
- 利妥昔单抗时代后生存改善不明显,需跨多线治疗研究进一步提升生存。
研究设计与样本
- 基于荷兰全国癌症登记的人群研究,纳入1989-2018年诊断的6232例LPL/WM患者。
- 按年龄分组(<65、66-75和>75岁)和四个日历时期分析。
主要发现
- 诊断后1年内接受抗肿瘤药物治疗的比例逐渐下降,2011-2018年约40%接受抗肿瘤治疗。
- 单纯化疗使用减少,化疗免疫治疗应用增加。
- 2014-2018年1596例患者中,地塞米松-利妥昔单抗-环磷酰胺是最常用方案,使用率从14%升至39%。
- 5年相对生存显著改善,1989-1995年三个年龄组分别为75%、65%、46%,2011-2018年分别为93%、85%、79%。
关键数值与推荐
- 5年相对生存:1989-1995年<65岁75%、66-75岁65%、>75岁46%;2011-2018年分别为93%、85%、79%。
- 2011-2018年约40%患者接受抗肿瘤治疗。
- 2014-2018年地塞米松-利妥昔单抗-环磷酰胺使用率从14%升至39%。
临床怎么用
- 初始观察等待在LPL/WM中应用广泛,尤其随时间增加。
- 含利妥昔单抗的化疗免疫治疗是常用一线策略,与生存改善相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
It is unclear how treatment advances impacted the population-level survival of patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia (LPL/WM). Therefore, we assessed trends in first-line therapy and relative survival (RS) among patients with LPL/WM diagnosed in the Netherlands between 1989 and 2018 (N = 6232; median age, 70 years; 61% males) using data from the nationwide Netherlands Cancer Registry. Patients were grouped into three age groups (<65, 66-75 and >75 years) and four calendar periods. Overall, treatment with anti-neoplastic agents within 1 year post-diagnosis gradually decreased over time, following a broader application of an initial watch-and-wait approach. Approximately 40% of patients received anti-neoplastic therapy during 2011-2018. Furthermore, use of chemotherapy alone decreased over time, following an increased application of chemoimmunotherapy. Detailed data among 1596 patients diagnosed during 2014-2018 revealed that dexamethasone-rituximab-cyclophosphamide was the most frequently applied regimen; its use increased from 14% to 39% between 2014 and 2018. The 5-year RS increased significantly over time, particularly since the introduction of rituximab in the early-mid 2000s. The 5-year RS during 1989-1995 was 75%, 65%, and 46% across the age groups compared to 93%, 85%, and 79% during 2011-2018. However, the survival improvement was less pronounced after 2011. Collectively, the impressive survival improvement may be accounted for by broader application of rituximab-containing therapy. The lack of survival improvement in the post-rituximab era warrants studies across multiple lines of therapy to further improve survival in LPL/WM.
引用
- Amaador K, Kersten MJ, Visser O, et al. Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population-based study in the Netherlands, 1989-2018. Br J Haematol. 2021. PMID: 34605017. doi:10.1111/bjh.17856
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。